| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
																	
																	Gainers SciSparc (NASDAQ: SPRC) shares increased by 28.2% to $5.68 during Monday's after-market session. The company's...
																	- Findings highlight the potential of antibiotic-eluting bioenvelopes to transform cardiac implantable electronic device (CIED)...
																	Lake Street analyst Frank Takkinen maintains Elutia (NASDAQ:ELUT) with a Buy and lowers the price target from $8 to $6.
																	
																	
																	- Transaction affirms the strength of Elutia's proprietary drug-eluting biologics platform and fully funds advancement of N...